Transdermal therapeutic fentanyl-system (TTS-F)

In Vivo

Volumn 18, Issue 5, 2004, Pages 633-642

  Mystakidou, Kyriaki ^a   Katsouda, Emmanuela ^a   Tsilika, Eleni ^a   Parpa, Efi ^a   Vlahos, Lambros ^b  

^a UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

Analgesic ladder; Cancer pain; Fentanyl; Non cancer pain; Opioid; Review

Indexed keywords

ALFENTANIL; ANALGESIC AGENT; ANESTHETIC AGENT; BUPRENORPHINE; BUTORPHANOL; CLONIDINE; DELTA OPIATE RECEPTOR; DOXAPRAM; ESTRADIOL; ESTRADIOL PLUS NORETHISTERONE ACETATE; FENTANYL; FENTANYL DERIVATIVE; GLYCERYL TRINITRATE; KAPPA OPIATE RECEPTOR; LIDOCAINE; METHADONE; MIRFENTANIL; MORPHINE; MU OPIATE RECEPTOR; NALOXONE; NICOTINE; OHM 3507; OPIATE; OPIATE ANTAGONIST; PRILOCAINE; REMIFENTANIL; SCOPOLAMINE; SHORT ACTING DRUG; SUFENTANIL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANALGESIA; ANESTHESIOLOGICAL TECHNIQUES; APNEA; BOLUS INJECTION; CANCER PAIN; CHRONIC PAIN; CLINICAL TRIAL; CONSTIPATION; COST UTILITY ANALYSIS; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DELIVERY SYSTEM; DRUG DEPENDENCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG METABOLISM; DRUG OVERDOSE; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; GASTROINTESTINAL SYMPTOM; GENERAL ANESTHESIA; HUMAN; INAPPROPRIATE VASOPRESSIN SECRETION; INCIDENCE; LIPOPHILICITY; MENTAL DISEASE; MYOCLONUS; NAUSEA; NEUROLOGIC DISEASE; NEUROPATHIC PAIN; NOCICEPTION; PHARMACODYNAMICS; POSTOPERATIVE ANALGESIA; PRACTICE GUIDELINE; PRURITUS; RESPIRATION DEPRESSION; REVIEW; SEDATION; SIDE EFFECT; SKIN MANIFESTATION; STANDARD; TITRIMETRY; TOXICITY TESTING; VOMITING; WITHDRAWAL SYNDROME; WORLD HEALTH ORGANIZATION;

EID: 6944233535     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (116)

1. Cherny NJ: New strategies in opioid therapy for cancer pain. Oncol Manag 9: 8-15, 2000.
2. [No Authors Listed]. Transdermal fentanyl: new preparation. An alternative to morphine. Prescrire Int 7: 137-40, 1998.
3. Grond S, Radbruch L and Lehmann KA: Clinical pharmacokinetics of transdermal opioids: focus on transdermal fentanyl. Clin Pharmacokinet 38: 59-89, 2000.
4. Lehmann KA and Zech D: Transdermal fentanyl: clinical pharmacology. J Pain Symptom Manage 7(3 Suppl): S8-16, 1992.
5. Payne R: Factors influencing quality of life in cancer patients: the role of transdermal fentanyl in the management of pain. Semin Oncol 25(3 Suppl 7): 47-53, 1998.
6. Vecht CJ and Sillevis Smitt PA: Transdermal opioid administration: the pain plaster. Ned Tijdschr Geneeskd 141: 821-3, 1997.
7. Anderson DT and Muto JJ: Duragesic transdermal patch: postmortem tissue distribution of fentanyl in 25cases. J Anal Toxicol 24: 627-34, 2000.
8. Mercadante S and Fulfaro F: Alternatives to oral opioids for cancer pain. Oncology 13: 215-20, 1999.
9. Portenoy RK, Southam MA, Gupta SK, Lapin J, Layman M, Inturrisi CE and Foley KM: Transdermal fentanyl for cancer pain. Repeated dose pharmacokinetics. Anesthesiology 78: 36-43, 1993.
10. Roy SD, Gutierrez M, Flynn GL and Cleary GW: Controlled transdermal delivery of fentanyl: characterizations of pressure-sensitive adhesives for matrix patch design. J Pharm Sci 85: 491-5, 1996.
11. Gupta SK, Southam M, Gale R and Hwang SS: System functionality and physiochemical model of fentanyl transdermal system. J Pain Symptom Manag 7(3 Suppl): S17-S26, 1992.
12. Berner B and John VA: Pharmacokinetic characterisation of transdermal delivery systems. Clin Pharmacokinet 26: 121-34, 1994.
13. Aiache JM: Transdermal therapeutic methods. Ann Cardiol Angeiol (Paris) 46: 441-9, 1997.
14. Conjeevaram R, Banga AK and Zhang L: Electrically modulated transdermal delivery of fentanyl. Pharm Res 19: 440-4, 2002.
15. Boucaud A, Machet L, Arbeille B, Machet MC, Sournac M, Mavon A, Patat F and Vaillant L: In vitro study of low-frequency ultrasound-enhanced transdermal transport of fentanyl and caffeine across human and hairless rat skin. Int J Pharm 228: 69-77, 2001.
16. Mystakidou K: E-TRANS fentanyl. ALZA. Curr Opin Investig Drugs 3: 463-9, 2002.
17. Wantanabe S, Pereira J, Hanson J and Bruera E: Fentanyl by continuous subcutaneous infusion for the management of cancer pain: a retrospective study. J Pain Symptom Manag 16: 323-6, 1998.
18. Scholz J, Steinfath M and Schulz M: Clinical pharmacokinetics of alfentanil, fentanyl and sufentanil. An update, Clin Pharmacokinet 31: 275-92, 1996.
19. Clotz MA and Nahata MC: Clinical uses of fentanyl, sufentanil, and alfentanil. Clin Pharm 10: 581-93, 1991.
20. Christie JM, Simmonds M, Patt R, Coluzzi P, Busch MA, Nordbrock E and Portenoy RK: Dose-titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain. J Clin Oncol 16: 3238-45, 1998.
21. Farrar JT, Cleary J, Rauck R, Busch M and Nordbrock E: Oral transmucosal fentanyl citrate: randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients. J Natl Cancer Inst 90: 611-6, 1998.
22. Pierard GE: Pharma clinics. How I treat, or preventing pain with "patches". Rev Med Liege 53: 586-7, 1998.
23. France CP, Ahn SC, Brockunier LL, Bagley JR, Brandt MR, Winsauer PJ and Moerschbaecher JM: Behavioral effects and binding affinities of the fentanyl derivative OHM3507. Pharm Biochem Behavior 59: 295-303, 1998.
24. France CP, Winger G, Seggel MR, Rice KC and Woods JH: Pharmacological profile of a potent, efficacious fentanyl derivative in rhesus monkeys. Psychopharmacology 109: 291-8, 1992.
25. Egger CM, Duke T, Archer J and Cribb PH: Comparison of plasma fentanyl concentrations by using three transdermal fentanyl patch sizes in dogs. Vet Surg 27: 159-66, 1998.
26. Wilkinson AC, Thomas ML 3rd and Morse BC: Evaluation of a transdermal fentanyl system in yucatan miniature pigs. Contemp Top Lab Anim Sci 40: 12-6, 2001.
27. Franks JN, Boothe HW, Taylor L, Geller S, Carroll GL, Cracas V and Boothe DM: Evaluation of transdermal fentanyl patches for analgesia in cats undergoing onychectomy. J Am Vet Med Assoc 217: 1013-20, 2000.
28. Carroll GL, Hooper RN, Boothe DM, Hartsfield SM and Randoll LA: Pharmacokinetics of fentanyl after intravenous and transdermal administration in goats. Am J Vet Res 60: 986-91, 1999.
29. Varvel JR, Shafer SL, Hwang SS, Coen PA and Stanski DR: Absorption characteristics of transdermally administered fentanyl. Anesthesiology 70: 928-34, 1989.
30. Holley FO and van Steennis C: Postoperative analgesia with fentanyl: pharmacokinetics and pharmacodynamics of constantrate i.v. and transdermal delivery. Br J Anaesth 60: 608-13, 1988.
31. Plezia PM, Kramer TH, Linford J and Hameroff SR: Transdermal fentanyl: pharmacokinetics and preliminary clinical evaluation. Pharmacotherapy 9: 2-9, 1989.
32. Holdsworth MT, Forman WB, Killilea TA, Nystrom KM, Paul R, Brand SC and Reynolds R: Transdermal fentanyl disposition in elderly subjects. Gerontology 40: 32-7, 1994.
33. Thompson JP, Bower S, Liddle AM and Rowbotham DJ: Perioperative pharmacokinetics of transdermal fentanyl in elderly and young adult patients. Br J Anaesth 81: 152-4, 1998.
34. Paut O, Camboulives J, Viard L, Lemoing JP and Levron JC: Pharmacokinetics of transdermal fentanyl in the peri-operative period in young children. Anaesthesia 55: 1202-7, 2000.
35. Collins JJ, Dunkel IJ, Gupta SK, Inturrisi CE, Lapin J, Palmer LN, Weinstein SM and Portenoy RK: Transdermal fentanyl in children with cancer pain: feasibility, tolerability,and pharmacokinetic correlates. J Pediatr 134: 319-23, 1999.
36. Poklis A: Fentanyl: a review for clinical and analytical toxicologists. J Toxicol Clin Toxicol 33: 439-47, 1995.
37. Bleeker CP, Bremer RC, Dongelmans DA, van Dongen RT and Crul BJ: Inefficacy of high-dose transdermal fentanyl in a patient with neuropathic pain, a case report. Eur J Pain 5: 325-9, 2001.
38. Alsahaf MH and Stockwell M: Respiratory failure due to the combined effects of transdermal fentanyl and epidural bupivacaine/diamorphine following radical nephrectomy. J Pain Sympt Manage 20: 210-3, 2000.
39. Hardwick WE Jr, King WD and Palmisano PA: Respiratory depression in a child unintentionally exposed to a transdermal fentanyl patch. South Med J 90: 962-4, 1997.
40. Ahmedzai S: Current strategies for pain control. Ann Oncol 8(Suppl 3): S21-4, 1997.
41. Edinboro LE, Poklis A, Trautman D, Lowry S, Backer R and Harvey CM: Fatal fentanyl intoxication following excessive transdermal application. J Forensic Sci 42: 741-3, 1997.
42. Klockgether-Radke A and Hildebrandt J: Opioid intoxication. Inappropriate administration of transdermal fentanyl. Anaesthesist 46 428-9, 1997.
43. Flannagan LM, Butts JD and Anderson WH: Fentanyl patches left on dead bodies - potential source of drug for abusers. J Forensic Sci 41: 320-1, 1996.
44. Marquardt KA, Tharratt RS and Musallam NA: Fentanyl remaining in a transdermal system following three days of continuous use. Ann Pharmacother 29: 969-71, 1995.
45. Frolich MA, Giannotti A, Modell JH and Frolich M: Opioid overdose in a patient using a fentanyl patch during treatment with a warming blanket. Anesth Analg 93: 647-8, 2001.
46. Low JA and Chye R: A pitfall to avoid when starting a patient on transdermal fentanyl. Aust Fam Physician 29: 1173-5, 2000.
47. Zuurmond WW, Meert TF and Noorduin H: Partial versus full agonists for opioid-mediated analgesia-focus on fentanyl and buprenorphine. Acta Anaesthesiol Belg 53: 193-201, 2002.
48. Han PK, Arnold R, Bond G, Janson D and Abu-Elmagd K: Myoclonus secondary to withdrawal from transdermal fentanyl: case report and literature review. J Pain Symptom Manage 23: 66-72, 2002.
49. Kramer C and Tawney M: A fatal overdose of transdermally administered fentanyl. J Am Osteopath Assoc 98: 385-6, 1998.
50. Jeal W and Benfield P: Transdermal fentanyl. A review of its pharmacological properties and therapeutic efficacy in pain control. Drugs 53: 109-38, 1997.
51. Murphy M and Carmichael AJ: Transdermal drug delivery systems and skin sensitivity reactions. Incidence and management. Am J Clin Dermatol 1: 361-8, 2000.
52. Mancuso G, Berdondini RM and Passarini B: Eosinophilic pustular eruption associated with transdermal fentanyl. J Eur Acad Dermatol Venerol 15: 70-2, 2001.
53. Kokko H, Hall PD and Afrin LB: Fentanyl-associated syndrome of inappropriate antidiruretic hormone secretion. Pharmacotherapy 22 1188-92, 2002.
54. Glerum LE, Egger CM, Allen SW and Haag M: Analgesic effect of the transdermal fentanyl patch during and after feline ovariohysterectomy. Vet Surg 30: 351-8, 2001.
55. Robinson TM, Kruse-Elliott KT, Markel MD, Pluhar GE, Massa K and Bjorling DE: A comparison of transdermal fentanyl versus epidural morphine for analgesia in dogs undergoing major orthopedic surgery. J Am Anim Hosp Assoc 35: 95-100, 1999.
56. Harvey-Clark CJ, Gilespie K and Riggs KW: Transdermal fentanyl compared with parenteral buprenorphine in postsurgical pain in swine: a case study. Lab Anim 34: 386-98, 2000.
57. Riviere JE and Papich MG: Potential and problems of developing transdermal patches for vetinary applications. Adv Drud Deliv Rev 50: 175-203, 2001.
58. Maxwell LK, Thomasy SM, Slovis N and Kollias-Baker C: Pharmacokinetics of fentanyl following intravenous and transdermal administration in horses. Equine Vet J 35: 484-90, 2003.
59. Foley PL, Henderson AL, Bissonette EA, Wimer GR and Feldman SH: Evaluation of fentanyl transdermal patches in rabbits: blood concentration and physiologic response. Comp Med 51: 239-44, 2001.
60. Kyles AE, Hardie EM, Hansen BD and Papich MG: Comparison of transdermal fentanyl and intramuscular oxymorphone on post-operative behaviour after ovariohysterectomy in dogs. Res Vet Sci 65: 245-51, 1998.
61. Gilbert DB, Motzel SL and Das SR: Postoperative pain management using fentanyl patches in dogs. Contemp Top Lab Anim Sci 42 21-6, 2003.
62. Iconomou G, Viha A, Vagenakis AG and Kalofonos HP: Transdermal fentanyl in cancer patients with moderate-to-severe pain: a prospective examination. Anticancer Res 20: 4821-4, 2000.
63. Donner B, Zenz M, Strumpf M and Raber M: Long-term treatment of cancer pain with transdermal fentanyl. J Pain Symptom Manage 15: 168-75, 1998.
64. Woodroffe MA and Hays H: Fentanyl transdermal system. Pain management at home. Can Fam Physician 43: 268-72, 1997.
65. Korte W and Morant R: Transdermal fentanyl in uncontrolled cancer pain: titration on a day-to-day basis as a procedure for safe and effective dose finding - a pilot study in 20 patients. Support Care Cancer 2: 123-7, 1994.
66. Herbst LH and Strause LG: Transdermal fentanyl use in hospice home-care patients with chronic cancer pain. J Pain Symptom Manage 7(3 Suppl): S54-7, 1992.
67. Miser AW, Narang PK, Dothage JA, Young RC, Sindelar W and Miser JS: Transdermal fentanyl for pain control in patients with cancer. Pain 37: 15-21, 1989.
68. Burza M, Ginobbi P, Fusco G, Laurenzi L, Tirelli W and Arcuri E: Transdermal route as an alternative to oral administration of opioids in cancer pain. Clin Ter 149: 277-80, 1998.
69. Vielvoye-Kerkmeer AP, Mattern C and Uitendaal MP: Transdermal fentanyl in opioid-naïve cancer pain patients: an open trial using transdermal fenntanyl for the treatment of chronic cancer pain in opioid-naïve patients and a group using codeine. J Pain Symptom Manage 19: 185-92, 2000.
70. Strupp C, Sudhoff T, Germing U, Hunerliturkoglu A, Schneider P, Niederste-Hollenberg A, Heyll A and Aul C: Transdermal fentanyl during high-dose chemotherapy and autologous stem cell support. Oncol Rep 7 659-61, 2000.
71. Radbruch L, Sabatowski R, Loick G, Kulbe C, Kasper M, Grond S and Lehmann KA: Constipation and the use of laxatives: a comparison between transdermal fentanyl and oral morphine. Palliat Med 14: 111-9, 2000.
72. Newshan G and Lefkowitz M: Transdermal fentanyl for chronic pain in AIDS: a pilot study. J Pain Sympt Manage 21: 69-77, 2001.
73. Hunt A, Goldman A, Devine T and Phillips M: FEN-GBR-14 Study Group. Transdermal fentanyl for pain relief in a pediatric palliative care population. Palliat Med 15: 405-12, 2001.
74. Dellemijn PL, van Duijn H and Vanneste JA: Prolonged treatment with transdermal fentanyl in neuropathic pain. J Pain Symptom Manage 16: 220-9, 1998.
75. Simpsom RK Jr, Edmondson EA, Constant CF and Collier C: Transdermal fentanyl as treatment for chronic low back pain. J Pain Symptom Manage 14: 218-24, 1997.
76. Christensen ML, Wang WC, Harris S, Eades SK and Wilimas JA: Transdermal fentanyl administration in children and adolescents with sickle cell pain crisis. J Pediatr Hematol Oncol 18: 372-6, 1996.
77. Korte W, de Stoutz N and Morant R: Day-to-day titration to initiate transdermal fentanyl in patients with cancer pain: short and long-term experiences in a prospective study of 39 patients. J Pain Symptom Manag 11: 139-46, 1996.
78. Zech DF, Grond SU, Lynch J, Dauer HG, Stollenwerk B and Lehmann KA: Transdermal fentanyl and initial dose-finding with patient-controlled analgesia in cancer pain. A pilot study with 20 terminally ill cancer patients. Pain 50: 293-301, 1992.
79. Maves TJ and Barcellos WA: Management of cancer pain with transdermal fentanyl: phase IV trial. J Pain Symptom Manag 7(3 suppl S58-S62, 1992.
80. Mystakidou K, Befon S, Kouskouni E, Gerolymatos K, Georgaki S, Tsilika E and Vlahos L: From codeine to transdermal fentanyl for cancer pain control: a safety and efficacy clinical trial. Anticancer Res 21: 2225-30, 2001.
81. Leppert W, Luczak J, Gorzelinska L and Kozikowska J: Research from the Palliative Care Department in Poznan on treatment of neoplasm pain with Durogesic (transdermal fentanyl). Przegl Lek 57: 59-64, 2000.
82. Sloan PA, Moulin DE and Hays H: A clinical evaluation of transdermal therapeutic system fentanyl for the treatment of cancer pain. J Pain Symptom Manage 16: 102-11, 1998.
83. Hammack JE, Mailliard JA, Loprinzi CL, Rospond RM, O'Fallon JR, Wilwerding MB, Reuter NF, Michalak JC, Fidler P and Miser AW: Transdermal fentanyl in the management of cancer pain in ambulatory patients: an open-label pilot study. J Pain Symptom Manage 12: 234-40, 1996.
84. Wong JO, Chin GL, Tsao CJ and Chang CL: Comparison of oral controlled-release morphine with transdermal fentanyl in terminal cancer pain. Acta Anaesthesiol Sin 35: 25-32, 1997.
85. Sevarino FB, Paige D, Sinatra RS and Silverman DG: Postoperative analgesia with parenteral opioids: does continuous delivery utilizing a transdermal opioid preparation effect analgesic efficacy or patient safety? J Clin Anesth 9: 173-8, 1997.
86. Miguel R, Kreitzer JM, Reinhart D, Sebel PS, Bowie J, Freedman G and Eissnkraft JB. Postoperative pain control with a new transdermal fentanyl delivery system. A multicenter trial. Anesthesiology 83: 470-7, 1995.
87. Burlow HH, Linnemann M, Berg H, Lang-Jensen T, LaCour S and Jonsson T: Respiratory changes during treatment of postoperative pain with high dose transdermal fentanyl. Anaesthesiol Scand 39: 835-9, 1995.
88. Broome IJ, Wright BM, Bower S and Reilly CS: Postoperative analgesia with transdermal fentanyl following lower abdominal surgery. Anaesthesia 50: 300-3, 1995.
89. Sandler AN, Baxter AD, Katz J, Samson B, Fredlander M, Norman P, Koren G, Roger S, Hull K and Klein J: A double-blind placebo-controlled trial of transdermal fentanyl after abdominal hysterectomy. Analgesic, respiratory, and pharmacokinetic effects. Anesthesiology 81: 1169-80, 1994.
90. Kilbride M, Morse M and Senagore A: Transdermal fentanyl improves management of postoperative hemorrhoidectomy pain. Dis Colon Rectum 37: 1070-2, 1994.
91. Lehmann KA, Einnolf C, Eberlein HJ and Nagel R: Transdermal fentanyl for the treatment of pain after major urological operations. A randomized double-blind comparison with placebo using intravenous patient-controlled analgesia. Eur J Clin Pharmacol 41: 17-21, 1991.
92. Caplan RA, Ready LB, Oden RV, Matsen FA, Nessly ML and Olsson GL: Transdermal fentanyl for postoperative pain management. A double-blind placebo study. JAMA 261: 1036-9, 1989.
93. Latasch L and Luders S: Transdermal fentanyl against postoperative pain. Acta Anaesthesiol Belg 40: 113-9, 1989.
94. Gourlay GK, Kowalski SR, Plummer JL, Cherry DA, Szekely SM, Mather LE, Owen H and Cousins MJ: The efficacy of transdermal fentanyl in the treatment of postoperative pain: a double-blind comparison of fentanyl and placebo systems. Pain 40: 21, 1990.
95. von Bormann B, Ratthey K, Schwetlick G, Schneider C, Muller H and Hempelmann G: Postoperative pain therapy by transdermal fentanyl. Anasth Intensivther Notfallmed 23: 3-8, 1998.
96. Ringe JD, Faber H, Bock O, Valentine S, Felsenberg D, Pfeifer M, Minne HW and Schwalen S: Transdermal fentanyl for the treatment of back pain caused by vertebral osteoporosis. Rheumatol Int 22: 199-203, 2002.
97. Noyes M and Irving H: The use of transdermal fentanyl in pediatric oncology palliative care. Am J Hosp Palliat Care 18: 411-6, 2001.
98. Stevens M, Esler R and Asher G: Transdermal fentanyl for the management of acute pancreatitis pain. Appl Nurs Res 15: 102-10, 2002.
99. Niemann T, Madsen LG, Larsen S and Thorsgaard N: Opioid treatment of painful chronic pancreatitis. Int J Pancreatol 27: 235-40, 2000.
100. Neighbors DM, Bell TJ, Wilson J and Dodd SL: Economic evaluation of the fentanyl transdermal system for the treatment of chronic moderate to severe pain. J Pain Symptom Manag 21: 129-43, 2001.
101. Elsner F, Radbruch L, Sabatowski R, Brunsch-Radbruch A, Loick G and Grond S: Switching opioids to transdermal fentanyl in a clinical setting. Schmerz 13: 273-8, 1999.
102. Cherny NJ, Chang V, Frager G, Ingham JM, Tieso PJ, Popp B, Portenoy RK and Foley KM: Opioid pharmacotherapy in the management of cancer pain: a survey of strategies used by pain physicians for the selection of analgesic drugs and routes of administration. Cancer 76 1283-93, 1995.
103. Mystakidou K, Parpa E, Tsilika E, Mavromati A, Smyrniotis V, Georgaki S and Vlahos L: Long-term management of noncancer pain with transdermal therapeutic system-fentanyl. J Pain 4: 298-306, 2003.
104. Mystakidou K, Tsilika E, Parpa E, Kouloulias V, Kouvaris I, Georgaki S and Vlahos L: Long-term cancer pain management in morphine, pre-treated and naïve patients with transdermal fentanyl. Int J Cancer 107: 486-92, 2003.
105. Radbruch L, Sabtowski R, Petzke F, Brunsch-Radbruch A, Grond S and Lehmann KA: Transdermal fentanyl for the management of cancer pain: a survey of 1005 patients. Palliat Med 15: 309-21, 2001.
106. Menten J, Desmedt M, Lossignol D and Mullie A: Longitudinal follow-up of TTS-fentanyl use in patients with cancer-related pain: results of a compassionate-use study with special focus on elderly patients. Curr Med Res Opin 18: 488-98, 2002.
107. Mystakidou K, Befon S, Tsilika E, Dardoufas K, Georgaki S and Vlahos L: Use of TTS fentanyl as a single opioid for cancer pain relief: a safety and efficiacy clinical trial in patients naïve to mild or strong opioids. Oncology 62: 9-16, 2002.
108. Enting RH, Oldenmenger WH, van der Rijt CC, Wilms EB, Elfrink EJ, Elswijk I and Sillevis Smitt PA: A prospective study evaluating the response of patients with unrelieved cancer pain to parenteral opioids. Cancer 94: 3049-56, 2002.
109. Grilo RM, Bertin P, Scotto di Fazano C, Coyral D, Bonnet C Vergne P and Treves R: Opioid rotation in the treatment of joint pain. A review of 67 cases. Joint Bone Spine 69: 491-4, 2002.
110. Donner B, Zenz M, Strumpf M and Raber M: Long-term treatment of cancer pain with transdermal fentanyl. J Pain Symptom Manag 15: 168-75, 1998.
111. Payne R, Mathias SD, Pasta DJ, Wanke LA, Williams R and Mahmoud R: Quality of life and cancer pain: satisfaction and side effects with transdermal fentanyl versus oral morphine. J Clin Oncol 16 1588-93, 1998.
112. Ahmedzai S and Brooks D: Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. The TTS-Fentanyl Comparative Trial Group. J Pain Symptom Manag 13: 254-61, 1997.
113. Mystakidou K, Parpa E, Tsilika E, Katsouda E, Kouloulias V, Kouvaris J, Georgaki S and Vlahos L: Pain management of cancer patients with transdermal fentanyl: a study of 1828 step I, II, & III transfers. J Pain 5(2): 119-132, 2004.
114. Allan L, Hays H, Jensen NH, de Waroux BL, Bolt M, Donald R and Kalso E: Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain. BMJ 322: 1154-8, 2001.
115. Mystakidou K, Parpa E, Tsilika E, Mavromati A, Smyrniotis V, Georgaki S and Vlahos L: Long-term management of noncancer pain with Transdermal Therapeutic System-Fentanyl. J Pain 4(6): 298-306, 2003.
116. van Bastelaere M, Rolly G and Abdullah NM: Postoperative analgesia and plasma levels after transdermal fentanyl for orthopedic surgery: double blind comparison with placebo. J Clin Anesth 7: 26-30, 1995.